Multifunctional immature dental pulp stem cells and therapeutic applications

Abstract

The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.

1 - 103 . (canceled) 
     
     
         104 . A pharmaceutical formulation comprising migratory immature dental pulp stem cells (IDPSCs) expressing CD73 (ecto-5′-nucleotidase), p53, and p75. 
     
     
         105 . The pharmaceutical formulation according to  claim 104 , wherein the IDPSCs express CD105, CD73, and CD90 and lack expression of CD45, CD34, and HLA-DR. 
     
     
         106 . The pharmaceutical formulation according to  claim 104 , wherein the IDPSCs express CD29 (integrin beta 1). 
     
     
         107 . The pharmaceutical formulation according to  claim 104 , wherein the migratory IDPSCs are in a unit dosage injectable form. 
     
     
         108 . The pharmaceutical formulation according to  claim 107 , wherein the unit dosage injectable form is selected from the group consisting of a solution, a suspension, a dispersion, and an emulsion. 
     
     
         109 . The pharmaceutical formulation according to  claim 108 , wherein the unit dosage injectable form is an aqueous dispersion. 
     
     
         110 . The pharmaceutical formulation according to  claim 109 , wherein the pH of the aqueous dispersion is between about 6.8 and about 7.5. 
     
     
         111 . The pharmaceutical formulation according to  claim 109 , wherein the ionic strength of the aqueous dispersion is between about 0.1 and about 0.2. 
     
     
         112 . The pharmaceutical formulation according to  claim 104 , further comprising a fluid lubricant. 
     
     
         113 . The pharmaceutical formulation according to  claim 104 , further comprising a carrier. 
     
     
         114 . The pharmaceutical formulation according to  claim 113 , wherein the carrier is a solvent or a dispersing medium. 
     
     
         115 . The pharmaceutical formulation according to  claim 113 , wherein the carrier comprises water, saline, or phosphate buffered saline. 
     
     
         116 . The pharmaceutical formulation according to  claim 104 , further comprising an additive and/or an excipient. 
     
     
         117 . The pharmaceutical formulation according to  claim 116 , wherein the additive and/or excipient are present in an amount of 0.001 to 50 weight percent. 
     
     
         118 . A pharmaceutical composition comprising migratory IDPSCs expressing CD73 (ecto-5′-nucleotidase), p53, and p75 and a pharmaceutically acceptable carrier or vehicle for cell therapy. 
     
     
         119 . The pharmaceutical composition according to  claim 118 , wherein the IDPSCs express CD105, CD73, and CD90 and lack expression of CD45, CD34, and HLA-DR. 
     
     
         120 . The pharmaceutical composition according to  claim 118 , wherein the IDPSCs express CD29 (integrin beta 1). 
     
     
         121 . The pharmaceutical composition according to  claim 118 , wherein the carrier is a solvent or a dispersing medium. 
     
     
         122 . The pharmaceutical composition according to  claim 118 , wherein the carrier comprises water, saline, or phosphate buffered saline. 
     
     
         123 . The pharmaceutical composition according to  claim 118 , further comprising a fluid lubricant. 
     
     
         124 . The pharmaceutical composition according to  claim 118 , wherein the vehicle is suitable for systemic administration.